Hyperuricemia and Incident Cardiovascular Disease and Noncardiac Vascular Events in Patients with Rheumatoid Arthritis

Table 3

Associations between hyperuricemia and cardiovascular disease/mortality in patients with rheumatoid arthritis (RA) and subjects without RA (non-RA).

	events in RA/non-RA	MI; HR (95% CI)	CVD; HR (95% CI)	HF; HR (95% CI)	Death; HR (95% CI)
		46/41	137/108	92/69	229/163
Model 1	RA	1.01; (0.50, 2.06)	1.00; (0.66, 1.52)	1.31; (0.82, 2.10)	2.00; (1.51, 2.64)
	Non-RA	1.84; (0.91, 3.72)	1.81; (1.14, 2.87)	1.88; (1.09, 3.25)	1.59; (1.12, 2.27)
Model 2	RA	0.86; (0.41, 1.80)	0.88; (0.57, 1.38)	1.18; (0.71, 1.95)	1.96; (1.45, 2.65)
	Non-RA	1.66; (0.81, 3.40)	1.59; (0.99, 2.55)	1.95; (1.13, 3.39)	1.57; (1.09, 2.24)
Model 3	RA	0.69; (0.31, 1.54)	0.94; (0.58, 1.51)	1.04; (0.61, 1.77)	1.85; (1.35, 2.55)
	Non-RA	1.37; (0.63, 2.96)	1.42; (0.84, 2.39)	1.59; (0.89, 2.84)	1.51; (1.03, 2.22)

Model 1: age, sex, and calendar year adjusted.
Model 2: Model 1, additionally adjusted for smoking, hypertension, obesity (BMI ≥ 30 kg/m²), diabetes mellitus, and dyslipidemia.
Model 3: Model 2, additionally adjusted for eGFR < 60, urate lowering therapy, alcoholism, and low-dose aspirin use.
MI: myocardial infarction; CVD: cardiovascular disease (composite of MI, revascularization procedures, angina, and heart failure.); HF: heart failure; Death: all-cause mortality; HR: hazard ratio; CI: confidence interval.